More importantly, in the TCGA cohort, we observed patients with TP53 mutations have higher UBE2C expression levels (Supplementary Figure S2), and the highest UBE2C levels were observed in the T4 stage of PCa (Figure 2D). The gene discussed is UBE2C; the disease is posterior cortical atrophy.